Low uptake in the RSV and COVID vaccine markets is not surprising, an analyst says, and could mean weak earnings for ...

Pfizer (NYSE:PFE) has reportedly succeeded in getting a U.K. court to invalidate two of GSK’s (NYSE:GSK) patents for its RSV ...

Millions of people who bought DNA tests from genetic testing service 23andme have been urged to delete their personal data ...

AbbVie’s immunology duo Skyrizi and Rinvoq is, in a rare blip this year, not leading the pharma DTC monthly rankings as ...

DNA analysis company 23andme has been in trouble lately: data was breached in a 2023 hack, and this September the entire ...

Test results are pending on a worker who had contact with infected herds, California officials report. Meanwhile, federal scientists are studying H5N1 genes in dairy workers in search of mutations ...

ViiV Healthcare to triple annual supply of long-acting HIV PrEP for low- and middle-income countries ...

Pfizer on Monday won a bid in a London court to invalidate two of GSK's patents relating to a respiratory syncytial virus ...

Chris Martin, Chairman and Non Executive Director of Myricx Bio said, “I am delighted to welcome Paolo to the board. He brings extensive leadership experience in R&D and commercialisation in the ...

Barclays analyst Emily Field maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £15.50.

After several high-profile failures, including BMS’ $1.5B breakup with Agenus, anti-TIGIT therapies are generating cautious ...

While Pfizer tackles weaker revenue for Covid-19 vaccines and drugs, along with an underwhelming launch of its respiratory ...